Skip directly to page options Skip directly to A-Z link
Volume 14, Number 8—August 2008
Dispatch

Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–20051

Justin R. Ortiz*2Comments to Author , Laurie Kamimoto*, Ronald E. Aubert†, Jianying Yao†, David K. Shay*, Joseph S. Bresee*, and Robert S. Epstein†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, GA, USA; †Medco Health Solutions, Inc., Franklin Lakes, New Jersey, USA;

Main Article

Figure 2

Figure 2 - Oseltamivir prescription rates/1,000 prescribers by specialty, United States, weeks 36–44, 2004 and 2005. Infectious diseases classification includes pediatric and adult infectious diseases specialists. All classifications are mutually exclusive. RR, rate ratio; CI, confidence interval.

Figure 2. Oseltamivir prescription rates/1,000 prescribers by specialty, United States, weeks 36–44, 2004 and 2005. Infectious diseases classification includes pediatric and adult infectious diseases specialists. All classifications are mutually exclusive. RR, rate ratio; CI, confidence interval.

Download

Main Article

1This study was presented, in part, at the Infectious Diseases Society of America annual meeting in Toronto, Ontario, Canada, October 14, 2006, and in poster form at the Options for the Control of Influenza Conference, Toronto, June 17, 2007.

2Current affiliation: University of Washington, Seattle, WA, USA.

Page created: July 12, 2010
Page updated: July 12, 2010
Page reviewed: July 12, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external